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1. INTRODUCTION {#mgg31014-sec-0005}
===============

The systemic lupus erythematosus (SLE) is an autoimmune disease characterized by increased auto‐antibody production, mainly directed to the cytoplasm and nuclear components that can lead to an inflammatory process promoted by immune complex deposition, affecting multiple organs and tissues (Rahman & Isenberg, [2008](#mgg31014-bib-0029){ref-type="ref"}). The etiology of the disease remains elusive; however, the involvement of environmental and genetic factors is well known (Tsokos, [2011](#mgg31014-bib-0041){ref-type="ref"}). CD40 is a type 1 transmembrane protein that belongs to the tumor necrosis factor receptor superfamily. CD40 is expressed on the surface of antigen‐presenting cells like dendritic cells, macrophages, and B cells, as a costimulatory molecule (Loskog & Eliopoulos, [2009](#mgg31014-bib-0023){ref-type="ref"}). Its ligand, CD40L (CD154), is a type 2 transmembrane protein expressed mostly on activated T CD4 + cells. The interaction between CD40 and CD154 is essential in the regulation of B cell proliferation, germinal center formation, immunoglobulin class switching, antibody production, and generation of memory B cells (Elgueta et al., [2009](#mgg31014-bib-0008){ref-type="ref"}; Toubi & Shoenfeld, [2004](#mgg31014-bib-0040){ref-type="ref"}). Several studies have shown the importance of CD40‐CD154 interaction in autoimmune diseases, and higher levels of soluble CD40 (sCD40) have been observed in SLE patients compared with control subjects (Petrackova et al., [2017](#mgg31014-bib-0026){ref-type="ref"}; Wagner et al., [2014](#mgg31014-bib-0044){ref-type="ref"}). However, the role of sCD40 form in the SLE pathogenesis is still poorly understood.

Two single nucleotide polymorphisms (SNPs) in the *CD40* gene (OMIM: \*109,535), −1 C \> T (rs1883832) and 6,048 G \> T (rs4810485), have been associated with different autoimmune diseases in several populations (Chen et al., [2015](#mgg31014-bib-0004){ref-type="ref"}; García‐Bermúdez et al., [2012](#mgg31014-bib-0011){ref-type="ref"}; Sokolova et al., [2013](#mgg31014-bib-0036){ref-type="ref"}). The −1 C \> T polymorphism locates in the Kozak sequence, which has an essential role in mRNA translation. Moreover polymorphic −1T allele seems implicated with lower protein production compared with −1C allele (Jacobson, Concepcion, Oashi, & Tomer, [2005](#mgg31014-bib-0016){ref-type="ref"}). Meanwhile, the 6,048 G \> T polymorphism, localized in the second intron of the *CD40* gene, has been associated with SLE in the Korean population (Joo et al., [2013](#mgg31014-bib-0017){ref-type="ref"}). In the Greek population, a significantly reduced *CD40* mRNA and protein expression have been observed in carriers of the GT and TT genotypes of 6,048 G \> T polymorphism compared with carriers of CC genotype (Vazgiourakis et al., [2011](#mgg31014-bib-0043){ref-type="ref"}). Both SNPs have been reported to be in strong linkage disequilibrium (*r^2^* = 0.95) in the Asian population (Chen et al., [2015](#mgg31014-bib-0004){ref-type="ref"}; Joo et al., [2013](#mgg31014-bib-0017){ref-type="ref"}).

In Mexican population, the *CD40* polymorphisms −1 C \> T and 6,048 G \> T did not found associated with rheumatoid arthritis; however, *CD40* mRNA levels were 1.5‐fold higher in RA patients compared with control subjects (Román‐Fernández et al., [2016](#mgg31014-bib-0031){ref-type="ref"}). This study aimed to evaluate the association between the −1 C \> T and 6,048 G \> T genetic variants with disease susceptibility, *CD40* mRNA expression, and sCD40 levels in SLE patients.

2. MATERIALS AND METHODS {#mgg31014-sec-0006}
========================

2.1. Editorial policies and ethical considerations {#mgg31014-sec-0007}
--------------------------------------------------

According to the ethical guidelines stated on the declaration of Helsinki (Brazil, 2013), the informed written consent was obtained from all patients and control subjects (CS) before their enrollment to the study. Investigation and Ethics committee of the Hospital General de Occidente approved the investigation (Number of approval 449/16).

2.2. Subjects {#mgg31014-sec-0008}
-------------

A total of 587 subjects were included in the study: 294 control subjects (CS) and 293 patients diagnosed with SLE according to the American College of Rheumatology criteria (Hochberg, [1997](#mgg31014-bib-0015){ref-type="ref"}). The patients were recruited from the Department of Rheumatology of the Hospital General de Occidente, Guadalajara, Mexico. The Mexican version of the Systemic Lupus Disease Activity Index (MexSLEDAI) (Guzmán, Cardiel, Arce‐Salinas, Sánchez‐Guerrero, & Alarcón‐Segovia, [1992](#mgg31014-bib-0014){ref-type="ref"}) and Systemic Lupus International Collaborating Clinics (SLICC) damage index (Gladman et al., [1996](#mgg31014-bib-0013){ref-type="ref"}) were applied to all SLE patients at the moment of enrollment. Patients were stratified according to the Mex‐SLEDAI score as follows: inactive (0--1), mild‐moderate (2--6) and severe (≥7) disease. The CS group included healthy subjects with no history of autoimmune diseases. All the participants were unrelated Mexican mestizo individuals from western Mexico with at least three generations of Mexican ancestry.

2.3. CD40 polymorphisms genotyping {#mgg31014-sec-0009}
----------------------------------

Blood samples were collected from all subjects, and genomic DNA was extracted following the modified Miller\'s method (Miller, Dykes, & Polesky, [1988](#mgg31014-bib-0025){ref-type="ref"}). Genetic variants rs1883832 (c.‐1C \> T) and rs4810485 (c.51 + 914G\>T) were genotyping using polymerase chain reaction‐restriction fragment length polymorphism (PCR‐RFLP) technique. For −1 C \> T SNP, the following primers were used: forward 5\'‐CCC CGA TAG GTG GAC CGC GAT TGG T‐3\' and reverse 5\'‐CCC GCC CTC TGA ACC CCC TAC CAG T‐3\'; whereas for 6,048 G \> T SNP the primers used were: forward 5\'‐TAT TTT TGT AGT TCC TCA TTC TGG A‐3\' and reverse 5\'‐GCC CCC CTT TAC CTC TTT CCA‐3\'. The PCR conditions were as described by Román‐Fernández et al. (Román‐Fernández et al., [2016](#mgg31014-bib-0031){ref-type="ref"}; Román‐Fernández, Muñoz‐Valle, & Palafox‐Sánchez, [2019](#mgg31014-bib-0032){ref-type="ref"}). The amplified 505 bp PCR product containing the −1 C \> T SNP was digested with 5 U of *Nco*I restriction enzyme (New England BioLabs^®^) at 37°C for 1 hr. The resulting restriction fragments were CC: 373 and 132 bp, CT: 505, 373, and 132 bp and TT: 505 bp. The 283 bp PCR product with the 6,048 G \> T SNP was digested with 5 U of *Msp*I restriction enzyme (New England BioLabs^®^) at 37°C for 2 hr. The restriction pattern for 6,048 G \> T genotyping was GG: 180 and 103 bp, GT: 283, 180, and 103 bp and TT: 283 bp.

2.4. CD40 mRNA expression analysis {#mgg31014-sec-0010}
----------------------------------

Relative quantification was performed by real‐time quantitative PCR (qPCR). RNA was extracted from peripheral blood leukocytes, using the Chomczynski and Sacchi method (Chomczynski & Sacchi, [1987](#mgg31014-bib-0005){ref-type="ref"}), from 22 CS and 21 SLE patients carrying the CC/GG, CT/GT, and the TT/TT genotypes for both polymorphisms (−1C \> T/6048G \> T). The RNA purity was determined by spectrophotometry (NanoDrop lite, Thermo Fisher Scientific), samples with A260/280 ratio below 1.7 were discarded. Total RNA (1 μg) was reversed transcribed using Oligo‐dT and Moloney murine leukemia transcriptase (Promega Corp.,) following the manufacturer\'s protocol. *CD40* (Hs01002915_g1) mRNA expression was determined using hydrolysis probes (TaqMan ®, Applied Biosystems, Thermo Fisher Scientific). *GAPDH* was used as the reference gene (Hs02786624_g1). qPCR was performed with 100 ng cDNA in a LightCycler 96 system (Roche Applied Science). All samples were run in triplicates. A validation experiment using serial dilutions of cDNA was conducted to verify amplification efficiencies for both genes. The data were analyzed with the relative expression software tool (REST) described by Pfaffl et al. (Pfaffl, Horgan, & Dempfle, [2002](#mgg31014-bib-0027){ref-type="ref"}).

2.5. Soluble CD40 quantification {#mgg31014-sec-0011}
--------------------------------

Serum samples were obtained from peripheral blood of SLE patients and CS and store at −20ºC until use. The sCD40 levels were determined using a commercial ELISA test (DCCD40 Quantikine ELISA kit \[R&D Systems^®^\]) according to manufacturer\'s conditions. The ELISA test sensitivity and detection limits are 5.56 and 19.5--1,250 pg/mL, respectively. All samples were run in duplicate and analyzed using a Multiskan^™^ Go Microplate Spectrophotometer (Thermo Fisher Scientific).

2.6. Statistical analysis {#mgg31014-sec-0012}
-------------------------

Statistical differences in the genotype and allele frequencies of *CD40* were compared using the chi‐square test and Fisher\'s exact test, when appropriate. The dominant genetic model was also evaluated (Shi & He, [2005](#mgg31014-bib-0034){ref-type="ref"}). Odds ratios (OR) and 95% confidence intervals (95% CI) were calculated to assess the risk of SLE in association with the *CD40* SNPs. Haplotypes inference was performed by EM algorithm using the SHEsis software (<http://analysis.bio-x.cn/myAnalysis.php>). The linkage disequilibrium was estimated using Lewontin\'s D' measure (Z. Li et al., [2009](#mgg31014-bib-0022){ref-type="ref"}). Groups were compared using the Mann‐Whitney U test and Kruskal‐Wallis test; Dunn\'s test was used to analyze differences between groups. Spearman\'s correlation coefficient was used to analyze the relationship between quantitative variables. *P*‐values \< .05 were considered statistically significant. Graph Pad Prism version 6.0 (GraphPad Software) was used for statistical analysis.

3. RESULTS {#mgg31014-sec-0013}
==========

3.1. Subjects demographic and clinical characteristics {#mgg31014-sec-0014}
------------------------------------------------------

The median age was 38 \[Interquartile Range (IQR) 27--56\] and 36.5 (IQR 28--47.7) years for CS and SLE patients, respectively. The female gender distribution was 96% in CS and 94% in SLE patients. For SLE patients, the median Mex‐SLEDAI score was 2 (IQR 0--4), and SLICC damage index was 0 (IQR 0--1), while the median of disease evolution was 4 (IQR 2--12) years. The main clinical manifestations were hematological cytopenias (75%, including lymphopenia, leukopenia, and thrombocytopenia), mucocutaneous (66.2%) and renal involvement (25.6%); from the latter active lupus nephritis and chronic kidney disease were observed in 15.9% and 9.7% of patients, respectively. The most common autoantibodies were anti‐dsDNA (57%), followed by anti‐RNP 33% and anti‐Ro 29%. SLE patients were under conventional treatment with prednisone (74.3%) with a median dosage of 10 (IQR 5--20) mg/day, azathioprine (54.9%) and antimalarials (52.1%).

3.2. Genotype and allele frequencies of CD40 gene polymorphisms {#mgg31014-sec-0015}
---------------------------------------------------------------

The genotype and allele frequencies of the −1 C \> T and 6,048 G \> T *CD40* gene polymorphisms in the CS and SLE patients are shown in Table [1](#mgg31014-tbl-0001){ref-type="table"}. The genotype distributions of both SNPs in the CS group were in Hardy‐Weinberg equilibrium (*p* \> .05). There were significant differences in the genotype and allele frequencies of both polymorphisms between CS and SLE patients. The −1T allele and −1TT genotype from −1 C \> T SNP were associated with a higher risk of SLE (OR = 1.424, 95% CI, 1.074--1.889, *p* = .014 and OR = 3.236, 95% CI, 1.247--8.397, *p* = .016, respectively). Likewise, the 6048T allele and 6048GT genotype were associated with a significant risk of SLE (OR = 1.442, 95% CI, 1.090--1.907, *p* = .010 and OR = 1.463, 95% CI, 1.038--2.061, *p* = .029, respectively).

###### 

Genotype, allele, and haplotype frequencies of *CD40* SNPs (−1 C \> T and 6,048 G \> T) in CS and SLE patients

  SNP                                                 CS *n* = 294 (%)   SLE *n* = 293 (%)   *p* value                OR (CI 95%)   *p* value
  --------------------------------------------------- ------------------ ------------------- ------------------------ ------------- -----------
  −1 C \> T (rs1883832)                                                                                                             
  CC                                                  193 (65.5)         169 (57.7)          .027                     1             ---
  CT                                                  95 (32.3)          107 (36.5)          1.286 \[0.911--1.816\]   .152          
  TT                                                  6 (2)              17 (5.8)            3.236 \[1.247--8.397\]   .016          
  Allele                                                                                                                            
  C                                                   481 (81.8)         445 (75.9)          .014                     1             ---
  T                                                   107 (18.2)         141 (24.1)          1.424 \[1.074--1.889\]   .014          
  Dominant                                                                                                                          
  CC                                                  193 (65.6)         169 (57.7)          .047                     1             ---
  CT + TT                                             101 (34.4)         124 (42.3)          1.402 \[1.004--1.958\]   .047          
  6,048 G \> T (rs4810485)                                                                                                          
  GG                                                  192 (65.3)         162 (55.3)          .03                      1             ---
  GT                                                  94 (32)            116 (39.6)          1.463 \[1.038--2.061\]   .029          
  TT                                                  8 (2.7)            15 (5.1)            2.222 \[0.918--5.376\]   .085          
  Allele                                                                                                                            
  G                                                   478 (81.3)         440 (75.1)          .010                     1             ---
  T                                                   110 (18.7)         146 (24.9)          1.442 \[1.090--1.907\]   .010          
  Dominant                                                                                                                          
  GG                                                  192 (65.3)         162 (553)           .013                     1             ---
  GT + TT                                             102 (34.7)         131 (44.7)          1.522 \[1.091--2.123\]   .013          
  Haplotype[\*](#mgg31014-note-0002){ref-type="fn"}   2n = 588 (%)       2n = 586 (%)                                               
  C G                                                 475 (80.7)         435 (74.2)          **‐**                    1             ---
  T T                                                 104 (17.7)         136 (23.2)          1.428 \[1.072--1.902\]   .014          

Abbreviations: CI, Confidence interval; CS, control subjects; OR, odds ratio; SLE, systemic lupus erythematosus; SNP, single nucleotide polymorphism.

Haplotype analysis included the −1 C \> T (rs1883832) and 6048G \> T (rs4810485) polymorphisms of *CD40* gene and all those with a frequency \<0.03 were ignored in the analysis.
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3.3. Haplotype analysis {#mgg31014-sec-0016}
-----------------------

The *CD40* gene −1 C \> T polymorphism was in strong linkage disequilibrium with the 6,048 G \> T polymorphism (D´ = 0.95). Haplotype frequencies are shown in Table [1](#mgg31014-tbl-0001){ref-type="table"}. The most frequent haplotypes were CG and TT (80.7% and 17.7% in CS and 74.2% and 23.2% in SLE patients, respectively). The TT haplotype was associated with a significantly increased risk of SLE compared with the CG haplotype (OR = 1.428, 95% CI, 1.072--1.902, *p* = .014).

3.4. CD40 mRNA and protein expression according to CD40 polymorphisms {#mgg31014-sec-0017}
---------------------------------------------------------------------

The sCD40 levels stratified according to the genotypes of −1 C \> T and 6,048 G \> T *CD40* polymorphisms in SLE patients are shown in Figure [1](#mgg31014-fig-0001){ref-type="fig"}c, d, f. The SLE subjects carrying the homozygous polymorphic genotypes showed decreased sCD40 levels \[−1TT/6048TT 257.2 (IQR 165.1--308.8) pg/mL\] compared with SLE subjects carriers of homozygous wildtype genotypes \[−1CC 392.3 (272.4--570.9) pg/mL) and 6048GG 366 (IQR 270.9--558.8) pg/mL\], *p* \< .05.

![*CD40* gene expression and sCD40 levels according to −1 C \> T (rs1883832) and 6,048 G \> T (rs4810485) polymorphisms. (a) *CD40* gene expression in CS and SLE patients, (b) sCD40 levels in CS and SLE patients, (c) and (d) sCD40 levels according to −1 C \> T (rs1883832) and 6,048 G \> T (rs4810485) genotypes; (e) *CD40* gene expression according to dominant model of −1 C \> T (rs1883832) polymorphism in SLE patients, and (f) sCD40 levels according to dominant model of −1 C \> T (rs1883832) polymorphism in SLE patients. The qualitative gene expression analysis was obtained through to Pfaffl\'s method. Mann‐Whitney U test, Kruskal‐Wallis test, and Dunn\'s post hoc test were used. Fc was obtained through the 2^‐ΔΔCq^ method. Data are shown in median and IQR. CS: Control subjects, Fc: Fold change, IQR: Interquartile range, SLE: Systemic Lupus Erythematosus](MGG3-7-e1014-g001){#mgg31014-fig-0001}

The *CD40* mRNA expression, according to the −1 C \> T SNP is shown in Figure [1](#mgg31014-fig-0001){ref-type="fig"}e. Following the dominant genetic model, the SLE patients carrying the −1T allele (CT + TT) displayed 1.26‐fold more *CD40* mRNA expression compared with carriers of −1CC genotype.

3.5. CD40 mRNA and protein expression according to clinical disease {#mgg31014-sec-0018}
-------------------------------------------------------------------

The SLE patients showed 1.33‐fold more *CD40* mRNA expression compared with the CS group (Figure [1](#mgg31014-fig-0001){ref-type="fig"}a). However, no significant differences regarding sCD40 levels were found in SLE in comparison with CS \[355.8 (IQR 257.2--528.5) pg/mL vs. 391.6 (IQR 336.7--454.2) pg/mL; *p* = .253\], Figure [1](#mgg31014-fig-0001){ref-type="fig"}b. No differences were observed in *CD40* mRNA expression according to disease activity, Figure [2](#mgg31014-fig-0002){ref-type="fig"}a. The SLE patients with severe disease activity (*n* = 17) \[576.9 (IQR 280--855) pg/mL\] displayed higher sCD40 levels in comparison with mild‐moderate activity (*n* = 60) \[345 (IQR 255.7--514.9) pg/mL\] and inactive patients (*n* = 42) \[338.1 (IQR 242.3--451.6) pg/mL\], however this difference was not significant (*p* = .073, Figure [2](#mgg31014-fig-0002){ref-type="fig"}b). In addition, no significant correlation between the sCD40 levels and the MexSLEDAI was observed (*r* = .073, *p* = .428). Nevertheless, the sCD40 levels were positively correlated with SLICC damage index (*r* = .272, *p* = .003, Figure [2](#mgg31014-fig-0002){ref-type="fig"}c). Of note, sCD40 levels showed a negative correlation with the estimated glomerular filtration rate \[eGFR, (*r* = −.313, *p* = .002, Figure [2](#mgg31014-fig-0002){ref-type="fig"}d)\] and sCD40 levels were higher in SLE patients with Kidney Disease Improving Global Outcomes (KDIGO) stage IV (*p* = .004, Figure [2](#mgg31014-fig-0002){ref-type="fig"}e) and chronic kidney disease (*p* = .006, Figure [2](#mgg31014-fig-0002){ref-type="fig"}f).

![*CD40* gene expression and sCD40 levels according to SLE activity. (a) *CD40* gene expression according to disease activity (b) sCD40 levels according to disease activity, (c) sCD40 levels and SLICC damage index correlation, (d) sCD40 levels and eGFR correlation, (e) association between sCD40 levels and KDIGO stage, and (f) sCD40 levels and CKD (SLE patients with an eGFR \< 50ml/min/1.73m2). The qualitative gene expression analysis was obtained through to Pfaffl\'s method. Mann‐Whitney U test, Kruskal‐Wallis test, Dunn\'s post hoc test, and Spearman rank correlation coefficient were used, Fc was obtained through the 2^‐ΔΔCq^ method. Data are shown in median and IQR. CS: Control Subjects, CKD: Chronic Kidney Disease, eGFR: estimated Glomerular Filtration Rate, KDIGO: Kidney Disease Improving Global Outcomes, Fc: Fold change, IQR: Interquartile range, SLE: Systemic Lupus Erythematosus](MGG3-7-e1014-g002){#mgg31014-fig-0002}

4. DISCUSSION {#mgg31014-sec-0019}
=============

CD40 is an important transmembrane protein that, together with its ligand CD154, plays a key role in T cell‐dependent humoral and adaptive cellular immunity (Toubi & Shoenfeld, [2004](#mgg31014-bib-0040){ref-type="ref"}). Therefore, several studies have focused on *CD40* genetic variants as susceptibility biomarkers for autoimmune diseases in diverse populations (Blanco‐Kelly et al., [2010](#mgg31014-bib-0001){ref-type="ref"}; Chen et al., [2015](#mgg31014-bib-0004){ref-type="ref"}; Joo et al., [2013](#mgg31014-bib-0017){ref-type="ref"}; M. Li et al., [2012](#mgg31014-bib-0021){ref-type="ref"}; Piotrowski, Lianeri, Wudarski, Olesińska, & Jagodziński, [2013](#mgg31014-bib-0028){ref-type="ref"}; Sokolova et al., [2013](#mgg31014-bib-0036){ref-type="ref"}; Teruel et al., [2012](#mgg31014-bib-0038){ref-type="ref"}; Wang et al., [2017](#mgg31014-bib-0045){ref-type="ref"}). However, in the Mexican population, the *CD40* polymorphisms as susceptibility markers for SLE have not been assessed. Hence, in this study, the −1 C \> T and 6,048 G \> T *CD40* polymorphisms, *CD40* mRNA expression, and soluble levels of CD40 were evaluated in a group of SLE patients from western Mexico. Our results showed a clear association for both *CD40* polymorphisms and SLE risk (*p* \< .05), contrary to a previous study in the Mexican population, who found no association between the −1 C \> T and 6,048 G \> T *CD40* genetic variants and rheumatoid arthritis (Román‐Fernández et al., [2016](#mgg31014-bib-0031){ref-type="ref"}). In western Mexican population, the overall polymorphic allele frequencies for both polymorphisms were lower to those found in Spanish (−1 C \> T: 27.7%, 6,048 G \> T: 27.2%) and Chinese (−1 C \> T: 41.1%, 6,048 G \> T: 50.2%) populations (Chen et al., [2015](#mgg31014-bib-0004){ref-type="ref"}; García‐Bermúdez et al., [2012](#mgg31014-bib-0011){ref-type="ref"}). These differences could be explained by the heterogeneity of the genetic background between populations; the western Mexican mestizo is a population with markedly European ancestry (64.9%), followed by Amerindian (30.8%) and African (≈15%) (Martínez‐Cortés et al., [2012](#mgg31014-bib-0024){ref-type="ref"}). We found an association for both *CD40* polymorphisms; −1 C \> T (OR = 1.424 \[1.074--1.889\], *p* = .014) and 6,048 G \> T (OR = 1.442 \[1.090--1.907\], *p* = .010), with a significant increased risk to SLE development in our population, similar to the reported previously for Asian populations (Chen et al., [2015](#mgg31014-bib-0004){ref-type="ref"}; Wu et al., [2016](#mgg31014-bib-0046){ref-type="ref"}). Furthermore, the highest risk was found in the −1TT genotype carriers (OR = 3.236 \[1.247--8.397\], *p* = .016). The *CD40* polymorphisms were in linkage disequilibrium, similar to that previously reported (Chen et al., [2015](#mgg31014-bib-0004){ref-type="ref"}; Joo et al., [2013](#mgg31014-bib-0017){ref-type="ref"}; Raychaudhuri et al., [2008](#mgg31014-bib-0030){ref-type="ref"}). The more prevalent haplotypes were CG and TT in SLE patients and CS; a significantly increased risk for SLE was found in the TT haplotype compared with the CG haplotype (OR = 1.428 \[1.072--1.902\], *p* = .014), similar to the one seen in Asian populations (Chen et al., [2015](#mgg31014-bib-0004){ref-type="ref"}; Wu et al., [2016](#mgg31014-bib-0046){ref-type="ref"}) but not in European‐Caucasian populations (Chadha et al., [2005](#mgg31014-bib-0002){ref-type="ref"}; Piotrowski et al., [2013](#mgg31014-bib-0028){ref-type="ref"}; Vazgiourakis et al., [2011](#mgg31014-bib-0043){ref-type="ref"}). It is worth to mention that the SLE studies for the Caucasians were carried out in regions of southeastern, central and western Europe and that the shared genetic background of the Mexican mestizo is with the Caucasian population belonging to southwest Europe; thus, the lack of concordance between our findings and those reported for European‐Caucasians could be due to differences in the genetic background between populations.

Given the association observed between the −1 C \> T and 6,048 G \> T *CD40* polymorphisms and risk of SLE in our population, the CD40 expression was evaluated according to the genotypes. We found lower sCD40 levels in SLE patients carriers of the risk −1T allele (*p* = .033). These results are in agreement with the functional impact attributed to the −1 C \> T SNP, localized within the Kozak sequence, on *CD40* mRNA translation. The recognition of the Kozak sequence GCCRCCaugG by the ribosome subunit can be affected by nucleotide changes in −3 and + 4 positions (M Kozak, [1987](#mgg31014-bib-0018){ref-type="ref"}). Mainly, polymorphisms in positions −1 to −3 of the mRNA are related to changes in protein yield (Marilyn Kozak, [2002](#mgg31014-bib-0019){ref-type="ref"}). The above was confirmed for *CD40* mRNA by Jacobson et al. (Jacobson et al., [2005](#mgg31014-bib-0016){ref-type="ref"}), who found that the presence of the −1T allele resulted in up to 32% less CD40 protein expression in transfected fibroblasts and suggested that this could be due to a modification on ribosome binding affinity reducing the efficiency of translation. Besides, they observed less CD40 protein expression on the surface of B cells from healthy subjects carrying the −1CT and −1TT genotypes compared with −1CC genotype carriers (Jacobson et al., [2005](#mgg31014-bib-0016){ref-type="ref"}). It is worth to mention that other authors have consistently made these observations on other cell populations (Field et al., [2015](#mgg31014-bib-0010){ref-type="ref"}; Skibola et al., [2008](#mgg31014-bib-0035){ref-type="ref"}; Vazgiourakis et al., [2011](#mgg31014-bib-0043){ref-type="ref"}).

In contrast to the sCD40 levels, we found a mild increment of *CD40* mRNA relative expression in the −1CT/‐1TT carriers in comparison with subjects carrying the −1CC genotype in CS and SLE. These findings suggest no dependence of *CD40* mRNA transcription and protein translation efficiency. Jacobson et al. have also suggested the above, who found similar results on unstimulated human B cells (Jacobson et al., [2005](#mgg31014-bib-0016){ref-type="ref"}). Altogether, our findings support the influence of the −1 C \> T *CD40* polymorphism on CD40 protein expression and suggest that the presence of the −1T allele also has an impact on protein translation efficiency for the transcripts encoding the CD40 soluble form.

Two main processes generate the sCD40 form: alternative splicing (Eshel et al., [2008](#mgg31014-bib-0009){ref-type="ref"}; Tone, Tone, Fairchild, Wykes, & Waldmann, [2001](#mgg31014-bib-0039){ref-type="ref"}) and proteolytic cleavage by the tumor necrosis factor‐α‐converting enzyme (TACE/ADAM‐17) (Contin, Pitard, Itai, et al., [2003](#mgg31014-bib-0007){ref-type="ref"}). The cleavage and release of CD40 in its soluble form seem to be dependent on cell contact, which could be a mechanism for regulating B cell activation (van Kooten et al., [1994](#mgg31014-bib-0042){ref-type="ref"}). Chatzigeorgiou et al. (Chatzigeorgiou et al., [2010](#mgg31014-bib-0003){ref-type="ref"}) reported increased levels of sCD40 in plasma and urine of Type 1 Diabetes mellitus (T1DM) patients compared with controls. Also, the membrane CD40 expression in peripheral blood mononuclear cells was correlated with plasma sCD40 levels, suggesting a relation between sCD40 expression and the inflammatory process. It has been reported that the soluble form of CD40 can inhibit immunoglobulin production by CD154‐activated B lymphocytes in vitro, which suggests that the soluble form can alter CD40/154 interaction, whence sCD40 is considered a decoy receptor (Contin, Pitard, Delmas, et al., [2003](#mgg31014-bib-0006){ref-type="ref"}).

In this study, the mRNA and protein CD40 expression in SLE patients showed no difference in comparison with CS, which is similar to what was observed in other studies (Chen et al., [2015](#mgg31014-bib-0004){ref-type="ref"}; Wu et al., [2016](#mgg31014-bib-0046){ref-type="ref"}). Since CD40 has an essential role in B cell activation and differentiation and thus in plasma cell production, CD40 expression was evaluated according to SLE disease activity. SLE patients with severe disease activity showed a trend toward increased sCD40 levels, which was not statistically significant. The treatment of the SLE patients could explain the above since most of them were under conventional treatment with prednisone and immunosuppressive drugs. Our findings suggest that despite treatment, there is a higher production of sCD40 in active lupus; considering the regulatory role attributed to sCD40, further studies addressing this concerning its production in active inflammatory diseases are needed.

The sCD40 levels were positively correlated with SLICC damage index; besides the type of damage was investigated in our SLE patients. A negative correlation of sCD40 levels with the eGFR was found, SLE patients with a KDIGO stage III and IV as well as those with chronic kidney disease showed higher sCD40 levels. Previously, it has been detected an increase of the soluble form of CD40 in serum from patients with uremic and impaired renal function, which was correlated with creatinine levels in uremic non‐hemodialyzed patients (Contin, Pitard, Delmas, et al., [2003](#mgg31014-bib-0006){ref-type="ref"}; Schwabe, Engelmann, Hess, & Fricke, [1999](#mgg31014-bib-0033){ref-type="ref"}). Similar to our findings, Xie et al. found a negative correlation of sCD40 form with declines in eGFR in a chronic kidney disease cohort (Xie et al., [2017](#mgg31014-bib-0047){ref-type="ref"}). Since the expression of CD40 is not restricted to B cells, it could be important to determine if, in SLE patients with chronic kidney disease, other cell types can produce sCD40. In particular the expression of CD40 has been reported on renal parenchymal and tubular epithelial cells, also sCD40 levels has been associated with renal fibrosis and local inflammatory (Gaweco, Mitchell, Lucas, McClatchey, & Van Thiel, [1999](#mgg31014-bib-0012){ref-type="ref"}; H. Li & Nord, [2009](#mgg31014-bib-0020){ref-type="ref"}; Starke, Wüthrich, & Waeckerle‐Men, [2007](#mgg31014-bib-0037){ref-type="ref"}). Majority of SLE patient develop renal involvement, and the autoantibodies play a key role in the pathogenesis. The release of soluble CD40 form could reflect a mechanism for regulating B cell activation and autoantibody production induced by T cell interaction or might be a control system to regulate damage in a target tissue. To the best of our knowledge, this is the first study that reported an association of sCD40 levels with damage, particularly impaired renal function in SLE patients, however additional studies in a prospective design should be considered to define the role of the soluble CD40 form in the course of SLE.

In conclusion, the *CD40* polymorphisms have an important role as genetic markers to SLE susceptibility in the western Mexican population. Also, higher sCD40 levels were associated with damage in SLE, particularly with impaired renal function. Although further studies are still necessary to get a better understanding of the role in SLE, the soluble levels of CD40 receptor could be considered as a potential marker of chronic kidney disease.
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